Quick Answer
A Cleveland Clinic study at ASCO 2026 found GLP-1 drugs like Ozempic reduced lung cancer progression by 50% and breast cancer by 43% in 10,000+ patients. Indian patients with cancer plus obesity or diabetes should discuss GLP-1 therapy with their doctor.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
Could the same injection used to treat diabetes and obesity also help stop cancer from spreading? A landmark new study from Cleveland Clinic, presented at ASCO 2026 — the world's largest cancer conference — suggests the answer may be yes. The findings show that patients with cancer who were taking GLP-1 drugs like Ozempic or Wegovy were up to 50% less likely to have their tumour progress to a more advanced stage. For Indian patients living with both obesity or diabetes and a cancer diagnosis, this is significant news.
What the New Research Found
Researchers at Cleveland Clinic, led by Dr. Mark Orland, studied the health records of more than 10,000 cancer patients from the TriNetX Global Health Research Network — one of the largest patient databases in the world. All patients had been diagnosed with one of seven common cancers: breast, colorectal, kidney, liver, lung, pancreatic, or prostate cancer. All were at stage 1, 2, or 3 when they started a GLP-1 drug such as semaglutide or tirzepatide after their diagnosis.
The researchers compared these patients to a matched group with the same cancer type, stage, and other health conditions, but who were taking a different diabetes drug — a DPP-4 inhibitor — instead of a GLP-1. The results were striking. In six of the seven cancer types studied, patients on GLP-1 drugs were less likely to have their cancer progress to stage 4. For four cancers, the benefit was statistically significant: people with lung cancer on GLP-1 drugs were 50% less likely to progress to stage 4, people with breast cancer were 43% less likely to progress, and people with colorectal cancer and liver cancer also showed meaningful reductions in progression. The study was presented at the American Society of Clinical Oncology (ASCO) annual meeting in May 2026 and has since been reported by NBC News, the American Association for Cancer Research, and leading oncology publications.
How Could a Weight Loss Drug Help Fight Cancer?
Researchers have proposed several mechanisms that could explain this surprising finding. First, tumour cells in several cancer types carry GLP-1 receptors on their surface. When GLP-1 drugs activate these receptors on cancer cells, they may disrupt a process called glycolysis — the way cancer cells convert glucose into the energy they need to grow and spread. In effect, the drug may cut off the tumour's energy supply at the cellular level.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
Second, GLP-1 drugs appear to modulate the immune system in ways that benefit cancer patients. They may boost the activity of T-cells — the immune cells that identify and destroy cancer — while also reducing the chronic inflammation that helps tumours thrive. Dr. Kelvin Lee, director of the Melvin and Bren Simon Comprehensive Cancer Center at Indiana University, described this as a one-two punch: GLP-1 drugs appear to work both directly on tumour cells and on the immune environment surrounding those cells.
The study also found an important clue: patients whose tumours had more GLP-1 receptors showed the greatest benefit. This suggests that in the future, tumour biology tests could help doctors predict which cancer patients would benefit most from GLP-1 therapy as an adjunct to standard treatment.
Why This Matters for Indian Patients
India faces an enormous cancer burden. The Indian Council of Medical Research (ICMR) estimates more than 1.5 million new cancer cases in 2026, with breast cancer and lung cancer among the most common. At the same time, India has one of the highest rates of obesity and type 2 diabetes in the world — both of which are established risk factors for many cancers, including breast, colorectal, and liver cancer.
This overlap is directly relevant to millions of Indian families. A patient with obesity and type 2 diabetes who is also dealing with a cancer diagnosis could potentially be a candidate for GLP-1 therapy to manage their metabolic conditions — and the Cleveland Clinic findings suggest that therapy could carry an important additional benefit: potentially slowing cancer progression at the same time. For many Indian patients, the decision of whether to start or continue a GLP-1 drug during cancer treatment has just become a much more important conversation to have with their specialist.
Important Caveats
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
It is essential to be clear about what this study does and does not prove. This was an observational study — it cannot prove that GLP-1 drugs directly caused the reduction in cancer progression. It is possible that patients who took GLP-1 drugs were healthier in other ways, or that better control of obesity and diabetes itself drove some of the benefit. Randomised clinical trials will be needed before any definitive conclusions are drawn.
GLP-1 drugs are not approved by any health authority — in India, the US, or elsewhere — for cancer treatment or cancer prevention. Dr. Orland himself stated that the most important takeaway right now is that GLP-1 drugs appear safe to use in cancer patients who need them for diabetes or obesity. Patients should not avoid them out of worry that they might interfere with cancer care. The evidence that they may also slow cancer progression is highly promising but not yet confirmed.
What Should You Do Next?
If you or a family member has been diagnosed with cancer and also has obesity or type 2 diabetes, bring this research to your next oncology or specialist appointment. Ask whether GLP-1 therapy is appropriate for your metabolic conditions — and whether the emerging evidence on cancer progression may be relevant to your situation. This is a conversation worth having now.
At MySurgery, our GLP-1 specialists work with patients managing complex health profiles, including those dealing with metabolic disease alongside serious conditions. We can help you understand whether GLP-1 therapy is right for you and connect you with the right specialist.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. NBC News — GLP-1 drugs may reduce the risk of cancer progressing, study suggests — https://www.nbcnews.com/health/cancer/glp-1-drugs-may-reduce-risk-cancer-progressing-study-suggests-rcna346364 2. American Association for Cancer Research — GLP-1 RAs May Prevent Metastatic Progression — https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-NW2026-0059/785409/GLP-1-RAs-May-Prevent-Metastatic-ProgressionGLP-1 3. Oncology Nursing News — GLP-1 Receptor Agonists Show Promise in ASCO 2026 Research — https://www.oncnursingnews.com/view/glp-1-receptor-agonists-show-promise-in-asco-2026-research
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.